Development and validation of a three-marker urine DNA methylation assay complementary to mpMRI for pre-biopsy risk stratification of clinically significant prostate cancer
This study developed and validated a non-invasive three-marker urine DNA methylation assay that, when combined with multiparametric MRI, significantly improves the sensitivity for detecting clinically significant prostate cancer compared to MRI alone, offering a promising tool for refining pre-biopsy risk stratification.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For millions of men, the path to a prostate cancer diagnosis begins with a simple blood test that measures a protein called PSA. When levels rise, it signals that something is wrong, but it does not say what. The prostate can swell from infection, from age, or from cancer, and the blood test cannot tell the difference. This uncertainty often leads to a second step: a needle biopsy, where doctors take small samples of tissue to look for cancer cells under a microscope. The goal of modern medicine is to find the dangerous, fast-growing tumors that need treatment while avoiding the biopsy for men who only have harmless conditions. To help with this, doctors now use a powerful type of camera called an MRI to take detailed pictures of the prostate before deciding who needs a needle. However, even the best camera sometimes misses a tumor or sees a shadow that isn't there, leaving doctors and patients in a difficult gray area.
A new study from researchers in South Korea explores a different way to look for trouble: by listening to the chemical whispers of the cancer itself. Instead of relying only on pictures, the team developed a test that checks urine for specific chemical tags on DNA. These tags, known as methylation, act like switches that turn genes on or off. In cancer cells, these switches are often flipped in the wrong direction. Because the prostate sits right next to the bladder, tiny fragments of DNA from prostate cells wash out into the urine. The researchers wanted to see if they could find these specific, cancer-related switches in a urine sample collected naturally, without any prior physical manipulation, and if this molecular clue could help the MRI make better decisions.
The team began by hunting for the right genetic switches. They examined tissue from men who had already undergone surgery to remove their prostate. By comparing the DNA from the cancerous parts of the organ with the healthy parts, they identified eight specific genes where the chemical tags were different in the cancer. They then narrowed this list down to three genes—CDYL, EMX2, and LRRC4—that showed the most promise. To prove these markers worked, they built a test that could detect the presence of these specific tags in urine. Crucially, they designed the test to work with urine that a man simply provides in a cup, without a doctor first performing a digital rectal exam to stimulate the prostate. This makes the process much simpler and less invasive for the patient.
The researchers then put their new test to the challenge. They collected urine samples from nearly one hundred men who were scheduled for a prostate biopsy because their doctors suspected cancer. Every man in the study also had an MRI scan before the biopsy. The researchers did not tell the doctors the results of the urine test; they kept the test results separate to see how well the test performed on its own and how it compared to the MRI. When they looked at the results, the urine test alone was good at finding cancer, catching about three-quarters of the cases, but it also gave some false alarms, flagging men who did not have the disease. The MRI was better at avoiding false alarms but missed more of the actual cancers.
The most significant finding came when the researchers combined the two methods. They asked a simple question: if either the MRI showed a suspicious spot or the urine test found the cancer markers, should the man get a biopsy? When they used this "either-or" approach, the ability to find the dangerous cancers jumped significantly. The combined strategy caught nearly ninety-two percent of the clinically significant cancers, a major improvement over using the MRI alone. This suggests that the urine test can find cancers that the camera misses, particularly in cases where the MRI image is unclear. For example, in a small group of men whose MRI results were ambiguous, the urine test correctly identified every single case of dangerous cancer.
The study also looked at what would happen if doctors used this combined information to decide who needs a biopsy. If they followed a rule where a biopsy was only done if both the MRI and the urine test were positive, they would have avoided many unnecessary procedures, but they would have also missed half of the dangerous cancers. Conversely, if they used the "either-or" rule, they would have caught almost all the dangerous cancers, but they would have performed fewer biopsies than they do now, saving about twenty-one percent of the men from the needle. The researchers emphasize that this is a projection based on their data, not a final rule for practice. They did not actually withhold biopsies from anyone in the study; every man was biopsied to confirm the truth.
The authors are careful to state that this urine test is not a magic bullet that replaces the need for a biopsy or the MRI. It is a tool that adds a layer of biological information to the anatomical pictures. The test works best when used alongside the MRI, not as a standalone replacement. The study also highlights that the test was developed and validated in a specific group of men who were already suspected of having cancer, so its performance might look different in a general screening population. Furthermore, the test is not perfect; it still misses some cancers and flags some healthy men. The researchers conclude that the next step is to run a large, forward-looking study where doctors actually use this combined information to decide who gets a biopsy, to see if it truly helps men avoid unnecessary procedures without missing the disease. For now, the work proves that a simple urine sample can provide a vital piece of the puzzle, offering a new way to see the invisible signs of prostate cancer.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.